The paper investigates how to allocate limited amyloid PET scans in Alzheimer’s research by comparing simple target‑aligned validation strategies to more complex uncertainty‑based sampling. Using the A4/LEARN PET archive, it shows that for the APOE4 carrier versus non‑carrier contrast, balancing scans by APOE4 status nearly matches the performance of a target‑specific scoring approach, while generic uncertainty sampling performs worse. For other analyses, such as age‑slope or cutoff‑indexed PET positivity, target‑specific scoring yields greater gains, underscoring that measurement allocation should align with the specific claim being validated.
arXiv:2606. 19371v1 Announce Type: cross Abstract: Alzheimer's disease (AD) is a fatal disorder that destroys memory and cognitive skills in the elderly population.
The paper introduces MCNet, a neural network that assigns a Modality Contribution Score (MCS) to each patient, indicating how much structural MRI versus amyloid PET drives the diagnostic decision for Alzheimer’s disease. Across 327 ADNI-3 participants, MCNet achieved strong three‑class staging (AUC = 0.881) and the MCS showed a clear, statistically significant increase in PET dominance from cognitively normal to AD. The method was validated on an independent OASIS‑3 cohort and compared favorably to SHAP, suggesting it can guide personalized imaging and clinical trial decisions.
arXiv:2607. 17442v1 Announce Type: new Abstract: Background.
The paper introduces OPAL, a held‑out decision test that evaluates follow‑up measurement rules in biological screens by freezing a rule and assessing unnecessary measurement, coverage, and value after cost against pre‑defined archive‑specific criteria. Using a six‑rule Cell Painting battery, the authors show that a high‑value rule would re‑image 96.01% of the library with a 97.14% false‑activation upper bound, illustrating that predicted value alone cannot justify replacing a fixed plan. In development, a sparse Cell Painting rule reduced added‑well burden 18.2‑fold but had a false‑discovery bound above 35%, leading the fixed plan to remain; similar analyses for LINCS–LJP and CTRP highlighted the need for fallback strategies and the importance of separating optimization from evidence. "whyItMatters":"OPAL provides a systematic way to determine whether a new measurement strategy truly improves experimental efficiency without compromising data quality, as demonstrated across multiple biological screening datasets."
arXiv:2610. 01278v1 Announce Type: new Abstract: Alzheimer's disease (AD) diagnosis requires sequential evidence acquisition under heterogeneous test costs and patient burden.
The paper introduces Observation‑Anchored Selective Assimilation (OASA) for forecasting tumor‑state proxies in post‑treatment glioma patients using serial MRI observations. OASA anchors the patient‑specific state with an intermediate observation and selectively updates it via a tiered rule and voxel‑wise soft gate, outperforming baseline methods in Dice score at certain thresholds. The approach is validated on 120 patient triplets and the code is publicly released.
The paper introduces RouteCert, a method for ensuring risk control in multimodal systems that acquire inputs adaptively. It shows that conditional calibration can remain valid even when the acquisition policy determines the calibration group, and provides two finite‑sample constructions: threshold‑free routing with terminal‑pattern calibration and simultaneous validation of policy‑pattern pairs. Experiments on a clinical ECG task and masked multimodal benchmarks demonstrate that RouteCert achieves low disagreement rates and competitive answered fractions while validating each acquisition stage separately.
arXiv:2608.30835v1 Announce Type: cross Abstract: Background and Objective: Quality control is a prerequisite for whole-slide image analysis, yet the benchmarks on which quality-control methods are c...
arXiv:2608. 03190v1 Announce Type: new Abstract: Neuro-oncology decisions require coordinated interpretation of serial MRI, pathology, molecular markers, treatment history, performance status, and evolving guidelines.
NeuronSifter is a framework for planning interventions in central nervous system microenvironments by converting treatment regimens into state‑conditional target‑occupancy fields and propagating them through microenvironment dynamics. It selects measurements based on their expected reduction in intervention loss, integrating typed outcomes into a unified posterior. In synthetic Alzheimer’s disease scenarios, occupancy conditioning improves trajectory probability scores and intervention ordering accuracy, and decision‑directed acquisition reduces terminal risk compared to a Bayesian experimental design planner.
arXiv:2604. 11305v3 Announce Type: replace Abstract: Conformal selection (CS) uses calibration data to identify test inputs whose unobserved outcomes are likely to satisfy a pre-specified minimal quality requirement, while controlling the false discovery rate (FDR).
The study evaluates whether a portfolio of compact, semantically named descriptor blocks can match the performance of a 2048‑dimensional CheMeleon embedding in low‑data molecular assays. Using a fixed 11‑dimensional physicochemical base and greedily adding provenance‑screened blocks, the portfolio achieves a mean test AUC of 0.762 across nine ADME/Tox assays, comparable to CheMeleon’s 0.764 and better than Mordred’s 0.756. The results meet a predeclared pooled parity threshold but not all per‑assay thresholds, and further analysis confirms the competitiveness of the auditable representation while highlighting unresolved assay‑level differences.